Aim: To identify risk factors for a non-favourable long term outcome with respect to Health Related Quality of Life (HRQoL) and fatigue after treated Lyme Neuroborreliosis (LNB).
INTRODUCTION
Lyme Neuroborreliosis (LNB) is usually effectively treated with antibiotics (1), but persisting complaints occur (2) (3) (4) . Objective neurological findings after treated LNB are usually mild, but symptoms such as musculoskeletal pain, fatigue, cognitive deficits and reduced Health Related Quality of Life (HRQoL) are commonly reported (5) (6) (7) (8) (9) (10) (11) (12) . If such symptoms persist for more than 6 months after a documented episode of Lyme disease treated with a generally accepted antibiotic regime, the symptoms are of such a severity that they result in reduction in previous level of functions, and there are no other obvious explanations of the symptoms, the condition is proposed defined as Post-Lyme Disease Syndrome (PLDS) (13). Despite several theories such as persisting infection, autoimmunity, disturbances in the hormone axis, anxiety, depression and permanent tissue damage, the underlying pathology of PLDS is still unknown (14) . Imaging of the brain does not show specific abnormalities (15, 16) and persistent infection is unlikely as prolonged antibiotic treatment does not improve the outcome permanently and is not recommended (7, (17) (18) (19) (20) .
It is important to increase our understanding of the remaining complaints after treated LNB, and one approach is to identify risk factors for a non-favorable outcome. It has been reported that fatigue, neurocognitive deficits, arthralgia and residual neurological findings are more common if the treatment is delayed (2, 3, 5, 8, 21) , but to our knowledge predictors of HRQoL has not been addressed in European LNB studies until now.
The aim of our study was to identify possible clinical, demographical and laboratory factors associated with reduced HRQoL and fatigue 30 months after antibiotic treatment in a cohort of LNB patients.
MATERIAL AND METHODS

Patients and variables
From 2004 to 2008 we included 102 consecutive adult patients diagnosed with LNB in a multicenter treatment trial in Southern Norway (22) . Out of these, 64 patients were recruited from two of the nine participating hospitals, covering the high endemic region of the Agder Counties. Fifty-seven of the 64 patients were included in the period May 2004-December 2007 and were all invited to participate in the current follow-up study. Fifty patients consented and were included. Neither the patients from the treatment trail who were not recruited to this follow-up study, nor the seven patients who were invited, but not included, differed from the 50 included patients regarding treatment or severity of the disease before and 4 months after treatment. The patients were treated with doxycycline (n=26) or ceftriaxone (n=24), and were classified as having definite (n=34) or possible (n=16) LNB according to the European Foundation of Neurological Society diagnostic guidelines (23) .
Mean pre-treatment symptom duration was 9.2 weeks (Standard Deviation (SD) =19), 10 patients had pre-treatment duration of symptoms > 6 weeks, four of them >6 months (104, 76, 52 and 28 weeks, respectively).
Forty of the patients (80%) presented with partial or complete Bannwart syndrome (facial palsy (n=8), other cranial nerve affection (n=4), paresis arm/leg (n=8), radiculitis (n=20) with lymphocytic CSF pleocytosis). Other affections were plexopathy (n=1), findings indicating CNS involvement (myelitis (n=1), ataxia (n=2) or confusion (n=1)), and recent onset subjective symptoms (n=5) (headache, joint pain, myalgias, malaise, asthenia). All assessments took place in the Department of Neurology at Sørlandet Hospital. The participants filled in the questionnaires Short Form-36 (SF-36) and the Fatigue Severity Scale (FSS) 30 months (range 27-34) after treatment. We collected demographical, laboratory and clinical data pre-treatment and at 4, 12 and 30 months after treatment. The patients were asked about comorbidity and previous or current psychiatric problems. All patients underwent a lumbar puncture pre-treatment, 42 at 4 months, 33 at 12 months, and 29 at 30 months. We analyzed cell-count, protein level, anti-Borrelia antibodies and oligoclonal bands in the cerebrospinal fluids (CSF). CXCL-13 level was assessed in all patients pretreatment and 10 patients at 30 months. Based on a previous study we chose a CXCL-13 cut-off concentration of > 0 ng/g total CSF protein (24) . Clinical outcome/burden of complaints was assessed by a composite clinical score (range 0-64) based on subjective reported complaints and clinical neurological findings (Table 1) . Table 1 Composite clinical score Lyme Neuroborreliosis patients. Previously published (22) Clinical outcome score is the sum of subjective and objective findings. Each item is scored 0 = no, 1 = mild, 2 = severe (maximum total score 64). * Left and right sides scored separately. 
RESULTS
Results of the univariate analyses of possible predictors of outcome are summarized in Table Table 2 patients had only subjective complaints, slight feeling of malaise (n=5), fatigue (n=15), pain (n=7), paraesthesias (n=7), memory (n=13) and concentration problems (n=9).
Ten patients reported previous or current psychiatric problems, two of them used antidepressive medication at the time of follow-up because of a depressive disease. The other eight patients had minor psychiatric problems in their medical history. Mean Montgomery and Åsberg Depression Rating Scale (MADRS (range 0-60)) score was low, 3.1 (SD=4.9) (previously published (9)), and does not indicate depression.
A second tick-bite followed by an erythema migrans occurred in five patients in the period between LNB and 30 months follow-up, and all five received 14 days of per oral antibiotics.
One patient had re-infection with LNB at follow up visit and was treated with intravenous ceftriaxone for 14 days.
Demographic and clinical factors
We found that pre-treatment symptom duration >6 weeks (B=-10. 
CSF findings
Due to missing data we analyzed the CSF variables separately. None of them reached a significance level of P= 0.05 or less in the univariate analyses or in the regression model.
Three patients (10%) had pleocytosis at 30 months follow-up (5, 6 and 66 white blood cell pr. 
DISCUSSION
We have previously found reduced HRQoL and more fatigue in Norwegian patients treated for LNB 30 months earlier as compared to matched controls (9) . In the present study we wanted to identify risk factors for a non-favourable long term outcome with respect to HRQoL and fatigue. We found that pre-treatment symptom duration > 6 weeks and noncomplete recovery at 4 or 12 months post-treatment were associated with reduced HRQoL, and that pre-treatment symptom duration more than 6 weeks, more complaints before treatment, and non-complete recovery 12 months after treatment were associated with a higher burden of fatigue 30 months after treatment. Demographic factors like age, gender and educational level and clinical factors like diagnostic accuracy, treatment option, involvement of the central nervous system, and coexisting diseases were not associated with HRQoL or fatigue burden in our cohort, neither were any of the assessed CSF findings pre-treatment or during follow-up like cell count, protein level, anti-Borrelia antibodies, oligoclonal bands or CXCL-13 levels.
The association between reduced HRQoL and non-complete recovery is not unexpected from a clinical point of view, as non-complete recovery in this present study was defined as a score of >1 on a composite clinical score based on subjective complains and objective findings.
The association between a non-favorable long term HRQoL, prolonged time before antibiotic treatment and a higher burden of pre-treatment symptoms allow us to speculate if a more serious disease and longer duration of the disease before treatment can cause more permanent neural damage, like in other CNS infections (25, 26) . Poorer long-term outcome in patients with pre-treatment signs of CNS involvement and/or high degree of CSF inflammation might have underscored such a theory, but we did not find such an association in our cohort, maybe due to a small sample size. Suggested theories of underlying pathological mechanisms for a poor HRQoL and fatigue after LNB are autoimmunity (27) and ongoing persistent infection (28) . We could not find laboratory support for any of these theories. None of our patients had elevated cell count at follow-up, except for one patient with a Borrelia re-infection. Some had slightly elevated CSF protein, presence of CSF oligoclonal bands and persistent intrathecal anti-Borrelia antibody production at follow-up, but these findings were not associated with a non-favorable outcome, neither were any CSF findings pre-treatment. Furthermore, normalized CSF CXCL-13 level at 30 months post-treatment argues against an ongoing
Borrelia infection, at least in the 10 patient who had their CSF analyzed for CXCL-13.
Overall, the CSF findings at follow-up in this study should be interpreted with caution due to many missing data, and further research is recommended to elucidate laboratory signs of autoimmunity in patients with persistent long-term complaints after treated LNB. Another debated theory of remaining complaints is that some patients might be more vulnerable because of previous or current psychiatric conditions (29) . We have shown in a previous study that patients in this cohort have the same amount of psychiatric comorbidity as a control group, and the MADRS scores were low (9).
We assessed the association between long-term HRQoL, fatigue and selected demographic, Some previous studies have found delayed treatment to be predictive of a worse outcome (2, 8, 21) . A US study including Quality of Life assessments found reduced HRQoL after Lyme disease as we did (5), others have not (20) . A previous publication on this south
Norwegian cohort showed that in addition to delayed treatment, female gender and high pretreatment CSF cell count were associated with non-complete clinical recovery one year after treatment (3). We did not find gender or pre-treatment CSF cell count to be predictive of the outcome at 30 months regarding HRQoL or fatigue. Whether the patients were treated with oral doxycycline or intravenous ceftriaxone, or had a definite or possible LNB did also not influence on the long-term HRQoL or fatigue in this cohort. This is in coherence with the treatment study showing similar efficacy of these two treatments (22) .
The strengths of our study are the prospective design, a well defined patient group, and use of validated and reliable questionnaires. The linear regression model allows us to do simultaneous assessment of multiple potential risk factors and to statistically explore their internal dependency of each other, and thus the analyses are more reliable than if only simple comparisons are made.
Weaknesses of our study are the many missing data regarding CSF analyses and the lack of a prospectively followed control group, but we have previously shown that there is a significant difference between patients with LNB and controls regarding HRQoL and fatigue 30 months after treatment in this cohort (9) . We asked about current medication at the time of the followup, but there is a possibility that we might have missed some information of interventions initiated by other doctors like pain killers or non-inflammatory medications.
There are still many unknown factors regarding potential risk factors of a non-favorable longterm outcome with respect to HRQoL and fatigue level after LNB, and our results are not applicable as prognostic hallmarks at an individual level. It seems reasonable though to avoid delay of antibiotic treatment, and to be aware of the possibility of fatigue after 30 months in those who have a more severe disease pre-treatment and do not recover completely after 12 months.
Conclusion
Pre-treatment symptom duration of LNB more than 6 weeks and non-complete recovery at 12 months seem to predict a reduced HRQoL 30 months after treatment. More clinical findings and symptoms before and non-complete recovery 12 months after treatment seem to predict a higher fatigue burden 30 months after treatment. No CSF findings pre-treatment were associated to reduced HRQoL or more fatigue, neither were CSF findings at follow-up, but the latter should be interpreted with caution due to missing data.
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